Navigation Links
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022
Date:10/28/2013

BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents—Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences' idelalisib, Roche/Genentech/Chugai/Glycart's obinutuzumab, Celgene's Revlimid and Pfizer's Afinitor—together with the continued use of rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will fuel more than 6 percent annual growth in the non-Hodgkin's lymphoma (NHL) drug market. In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, sales will exceed $10 billion in 2022, with the kinase inhibitors ibrutinib and idelalisib comprising more than one-fifth of market share. These two agents will launch as treatments for multiple NHL subpopulations, and their use in combination with existing therapies, as well as monotherapies, will ensure that they will significantly add to the overall size of the market. The anticipated approval of Revlimid in the diffuse large B-cell lymphoma maintenance setting will also trigger significant market growth.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Non-Hodgkin's Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries' Treanda/Levact/Treakisym/Ribomustin, a cytotoxic chemotherapy that is becoming more and more entrenched in the treatment of NHL, will continue to experience an increase in use across most NHL subpopulations, but its sales will decline as a result of generic entry.

"New therapies entering the market will change the way NHL patients are treated by 2022," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "Of particular interest are the entries of the kinase inhibitors ibrutinib and idelalisib, which are poised to have a tremendous impact on the treatment of NHL patients, especially those with relapsed/refractory chronic lymphocytic leukemia and follicular lymphoma, but also mantle cell lymphoma. The anticipated approval of obinutuzumab will also impact how some NHL patients are managed, as the drug has been shown to be more efficacious than rituximab in certain subpopulations."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
4. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
5. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
8. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
9. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... 2016  Memorial Hermann Health System has teamed up ... to bring a one-of-a-kind experience to pediatric patients at ... such as 360-degree video and Google Cardboard, Howard was ... – giving the patients and their families an unexpected, ... caught on video . Memorial Hermann ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of ... perfection, go out of their way to be romantic, and may exaggerate a strength ... at any online dating profile. , A recent study from Queendom.com , ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology ... for the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards ... Executive Forum and Awards Gala on March 15, 2016 at the Westin Peachtree ...
Breaking Medicine News(10 mins):